News

Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
Environmental exposure to phthalates and dementia with Lewy bodies: contribution of metabolomics.

  • Agin A
  • Blanc F
  • Bousiges O
  • Villette C
  • Philippi N
  • Demuynck C
  • Martin-Hunyadi C
  • Cretin B
  • Lang S
  • Zumsteg J
  • Namer IJ
  • Heintz D
The cerebral blood flow deficits in Parkinson's disease with mild cognitive impairment using arterial spin labeling MRI.

  • Arslan DB
  • Gurvit H
  • Genc O
  • Kicik A
  • Eryurek K
  • Cengiz S
  • Erdogdu E
  • Yildirim Z
  • Tufekcioglu Z
  • Uluğ AM
  • Bilgic B
  • Hanagasi H
  • Tuzun E
  • Demiralp T
  • Ozturk-Isik E
Neuropathological features associated with basal forebrain atrophy in Alzheimer's disease.

  • Teipel SJ
  • Fritz HC
  • Grothe MJ
  • Alzheimer´s Disease Neuroimaging Initiative.
GBA variation and susceptibility to multiple system atrophy.

  • Wernick AI
  • Walton RL
  • Koga S
  • Soto-Beasley AI
  • Heckman MG
  • Gan-Or Z
  • Ren Y
  • Rademakers R
  • Uitti RJ
  • Wszolek ZK
  • Cheshire WP
  • Dickson DW
  • Ross OA
Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers.

  • Mangesius S
  • Mariotto S
  • Ferrari S
  • Pereverzyev S Jr
  • Lerchner H
  • Haider L
  • Gizewski ER
  • Wenning G
  • Seppi K
  • Reindl M
  • Poewe W
In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.

  • Costa MDC
  • Radzwion M
  • McLoughlin HS
  • Ashraf NS
  • Fischer S
  • Shakkottai VG
  • Maciel P
  • Paulson HL
  • Öz G
Neuropsychological tests are useful for predicting comorbidities of idiopathic normal-pressure hydrocephalus.

  • Kamohara C
  • Nakajima M
  • Kawamura K
  • Akiba C
  • Ogino I
  • Xu H
  • Karagiozov K
  • Arai H
  • Miyajima M
Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism.

  • Cerroni R
  • Liguori C
  • Stefani A
  • Conti M
  • Garasto E
  • Pierantozzi M
  • Mercuri NB
  • Bernardini S
  • Fucci G
  • Massoud R
Clinical applications of neurochemical and electrophysiological measurements for closed-loop neurostimulation.

  • Price JB
  • Rusheen AE
  • Barath AS
  • Rojas Cabrera JM
  • Shin H
  • Chang SY
  • Kimble CJ
  • Bennet KE
  • Blaha CD
  • Lee KH
  • Oh Y

Press releases, workshop summaries, and editorials

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.

AMP PD

 

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”